• Igor Aurer, Zdravko Mitrović, Ivo Radman, Jasminka Kovacević-Metelko, Damir Nemet, Ranka Serventi-Seiwerth, Ranka Stern-Padovan, Jasminka Jakic-Razumović, Marin Nola, Silva Zupancić-Salek, Dubravka Sertić, and Boris Labar.
• Zavod za hematologiju, Klinika za unutarnje bolesti Medicinskog fakulteta i Klinickoga bolnickog centra, Zagreb.
• Lijec Vjesn. 2004 Nov 1; 126 (11-12): 307-11.

AbstractIndolent Non-Hodgkin's lymphomas (NHL) are a group of slowly progressive immune system malignancies that cannot be cured with conventional treatment. Rituximab is an anti-CD20 monoclonal antibody that has recently become a part of the standard treatment of B-cell lymphoid malignancies. Here we present our experience in 25 patients with indolent NHL treated with rituximab with or without chemotherapy. Rituximab was administered at 3-4 week intervals in the standard dose of 375 mg/m2. 88% of the patients responded, 16 achieved a complete and 6 partial remission. Estimated 2-year actuarial survival is 63%. Response and survival rates were significantly better in patients with favorable prognosis (lower IPI score). Adverse effects related to rituximab occurred in 2 patients and were mild. Our results are completely comparable to previously reported studies and show that rituximab is effective and safe for the treatment of indolent B-cell NHL.

21 keywords...

hide…